Symbols / KALV $16.60 -1.34%
KALV Chart
About
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 838.82M |
| Enterprise Value | 823.61M | Income | -203.10M | Sales | 1.43M |
| Book/sh | 0.34 | Cash/sh | 6.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | 270 | IPO | — |
| P/E | — | Forward P/E | -11.21 | PEG | — |
| P/S | 588.23 | P/B | 49.39 | P/C | — |
| EV/EBITDA | -4.08 | EV/Sales | 577.57 | Quick Ratio | 5.16 |
| Current Ratio | 5.37 | Debt/Eq | 1662.33 | LT Debt/Eq | — |
| EPS (ttm) | -3.94 | EPS next Y | -1.48 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-24 | ROA | -60.98% |
| ROE | -190.18% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -3.36% | Profit Margin | 0.00% | Shs Outstand | 50.55M |
| Shs Float | 27.24M | Short Float | 42.92% | Short Ratio | 29.34 |
| Short Interest | — | 52W High | 19.00 | 52W Low | 9.23 |
| Beta | -0.29 | Avg Volume | 990.72K | Volume | 214.57K |
| Target Price | $34.00 | Recom | Strong_buy | Prev Close | $16.82 |
| Price | $16.59 | Change | -1.34% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$34.00
Mean price target
2. Current target
$16.56
Latest analyst target
3. DCF / Fair value
$-35.68
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$16.56
Low
$22.00
High
$39.00
Mean
$34.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-09 | main | HC Wainwright & Co. | Buy → Buy | $37 |
| 2026-01-09 | main | Needham | Buy → Buy | $35 |
| 2026-01-06 | main | Needham | Buy → Buy | $32 |
| 2025-12-04 | reit | Needham | Buy → Buy | $28 |
| 2025-11-11 | main | Citizens | Market Outperform → Market Outperform | $28 |
| 2025-09-12 | reit | Needham | Buy → Buy | $28 |
| 2025-09-12 | main | JMP Securities | Market Outperform → Market Outperform | $28 |
| 2025-07-11 | reit | HC Wainwright & Co. | Buy → Buy | $27 |
| 2025-07-08 | main | JMP Securities | Market Outperform → Market Outperform | $27 |
| 2025-07-08 | main | HC Wainwright & Co. | Buy → Buy | $27 |
| 2025-07-07 | main | Leerink Partners | Outperform → Outperform | $20 |
| 2025-04-08 | reit | Needham | Buy → Buy | $28 |
| 2025-03-26 | reit | Needham | Buy → Buy | $28 |
| 2025-03-26 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $19 |
| 2025-03-26 | main | Jones Trading | Buy → Buy | $30 |
| 2025-03-14 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-03-13 | reit | Needham | Buy → Buy | $28 |
| 2025-03-03 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $19 |
| 2025-01-31 | init | JMP Securities | — → Market Outperform | $19 |
| 2025-01-07 | init | TD Cowen | — → Buy | $30 |
- KalVista Pharmaceuticals (KALV) Projected to Post Quarterly Earnings on Tuesday - MarketBeat ue, 17 Mar 2026 06
- KalVista Pharmaceuticals: Has Potential But With Caveats (NASDAQ:KALV) - Seeking Alpha hu, 12 Mar 2026 15
- KalVista Stock Pre-Market (-0.2%): CEO Stock Sale for Tax Purposes Reported in SEC Filing - Trefis Wed, 11 Mar 2026 16
- KalVista Pharmaceuticals Stock Sees RS Rating Jump To 86 - Investor's Business Daily Wed, 11 Mar 2026 19
- New KalVista hire receives options on 6,750 company shares - Stock Titan Wed, 04 Mar 2026 12
- $KALV stock is up 18% today. Here's what we see in our data. - Quiver Quantitative Fri, 09 Jan 2026 08
- Does KalVista Pharmaceuticals (KALV) Have the Potential to Rally 117.98% as Wall Street Analysts Expect? - Yahoo Finance hu, 15 Jan 2026 08
- KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart - Stocktwits hu, 05 Mar 2026 19
- KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally? - Nasdaq hu, 10 Jul 2025 07
- Boxer Capital Management LLC Decreases Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat Sun, 15 Mar 2026 11
- Early HAE pill helps patients treat more attacks, models show near-90% relief - Stock Titan Mon, 02 Mar 2026 08
- KALVISTA PHARMACEUTICALS Earnings Preview: Recent $KALV Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative ue, 02 Sep 2025 07
- What is HC Wainwright's Estimate for KALV FY2027 Earnings? - MarketBeat Fri, 13 Mar 2026 14
- [Form 4] KalVista Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan ue, 24 Feb 2026 08
- Equities Analysts Issue Forecasts for KALV Q2 Earnings - MarketBeat Mon, 16 Mar 2026 05
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 6693 | 107633.0 | — | Sale at price 16.08 per share. | PALLEIKO BENJAMIN L | Chief Executive Officer | — | 2026-03-09 00:00:00 | D |
| 1 | 15625 | nan | — | — | PALLEIKO BENJAMIN L | Chief Executive Officer | — | 2026-03-06 00:00:00 | D |
| 2 | 1767 | 27507.0 | — | Sale at price 15.57 per share. | PIEKOS BRIAN | Chief Financial Officer | — | 2026-02-23 00:00:00 | D |
| 3 | 3975 | 61878.0 | — | Sale at price 15.57 per share. | SWEENY NICOLE | Officer | — | 2026-02-23 00:00:00 | D |
| 4 | 5354 | 83345.0 | — | Sale at price 15.57 per share. | AUDHYA PAUL K | Officer | — | 2026-02-23 00:00:00 | D |
| 5 | 10034 | 156197.0 | — | Sale at price 15.57 per share. | PALLEIKO BENJAMIN L | Chief Executive Officer | — | 2026-02-23 00:00:00 | D |
| 6 | 4347 | 67669.0 | — | Sale at price 15.57 per share. | YEA CHRISTOPHER M | Officer | — | 2026-02-23 00:00:00 | D |
| 7 | 11250 | nan | — | — | SWEENY NICOLE | Officer | — | 2026-02-20 00:00:00 | D |
| 8 | 11250 | nan | — | — | AUDHYA PAUL K | Officer | — | 2026-02-20 00:00:00 | D |
| 9 | 23250 | nan | — | — | PALLEIKO BENJAMIN L | Chief Executive Officer | — | 2026-02-20 00:00:00 | D |
Financials
| Line Item | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 479.22K | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -175.61M | -127.29M | -94.32M | -78.63M |
| TotalUnusualItems | 2.28M | 1.46M | -49.00K | -2.12M |
| TotalUnusualItemsExcludingGoodwill | 2.28M | 1.46M | -49.00K | -2.12M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -183.44M | -126.64M | -92.91M | -82.34M |
| ReconciledDepreciation | 941.00K | 816.00K | 718.00K | 564.00K |
| EBITDA | -173.33M | -125.83M | -94.37M | -80.75M |
| EBIT | -174.27M | -126.64M | -95.09M | -81.31M |
| NetInterestIncome | 650.00K | 3.90M | 2.23M | 1.09M |
| InterestExpense | 5.79M | 0.00 | ||
| InterestIncome | 6.43M | 3.90M | 2.23M | 1.09M |
| NormalizedIncome | -185.25M | -128.11M | -92.86M | -80.22M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -183.44M | -126.64M | -92.91M | -82.34M |
| TotalExpenses | 182.98M | 131.99M | 95.09M | 81.31M |
| TotalOperatingIncomeAsReported | -188.00M | -140.44M | -110.87M | -96.61M |
| DilutedAverageShares | 49.65M | 36.79M | 27.89M | 24.47M |
| BasicAverageShares | 49.65M | 36.79M | 27.89M | 24.47M |
| DilutedEPS | -3.69 | -3.44 | -3.33 | -3.36 |
| BasicEPS | -3.69 | -3.44 | -3.33 | -3.36 |
| DilutedNIAvailtoComStockholders | -183.44M | -126.64M | -92.91M | -82.34M |
| NetIncomeCommonStockholders | -183.44M | -126.64M | -92.91M | -82.34M |
| NetIncome | -183.44M | -126.64M | -92.91M | -82.34M |
| NetIncomeIncludingNoncontrollingInterests | -183.44M | -126.64M | -92.91M | -82.34M |
| NetIncomeContinuousOperations | -183.44M | -126.64M | -92.91M | -82.34M |
| TaxProvision | 3.39M | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -180.05M | -126.64M | -92.91M | -82.34M |
| OtherIncomeExpense | 2.28M | 1.45M | -53.00K | -2.12M |
| OtherNonOperatingIncomeExpenses | -3.00K | -10.00K | -4.00K | -1.00K |
| GainOnSaleOfSecurity | 2.28M | 1.46M | -49.00K | -2.12M |
| NetNonOperatingInterestIncomeExpense | 650.00K | 3.90M | 2.23M | 1.09M |
| InterestExpenseNonOperating | 5.79M | 0.00 | ||
| InterestIncomeNonOperating | 6.43M | 3.90M | 2.23M | 1.09M |
| OperatingIncome | -182.98M | -131.99M | -95.09M | -81.31M |
| OperatingExpense | 182.98M | 131.99M | 95.09M | 81.31M |
| OtherTaxes | -5.01M | -8.45M | -15.79M | -15.30M |
| ResearchAndDevelopment | 71.71M | 86.17M | 80.28M | 70.17M |
| SellingGeneralAndAdministration | 116.29M | 54.28M | 30.59M | 26.45M |
| GeneralAndAdministrativeExpense | 116.29M | 54.28M | 30.59M | 26.45M |
| OtherGandA | 116.29M | 54.28M | 30.59M | 26.45M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-04-30 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 49.76M | 42.52M | 34.17M | 24.55M |
| ShareIssued | 49.76M | 42.52M | 34.17M | 24.55M |
| TotalDebt | 6.31M | 7.32M | 8.23M | 8.19M |
| TangibleBookValue | 95.39M | 206.58M | 161.03M | 185.09M |
| InvestedCapital | 95.39M | 206.58M | 161.03M | 185.09M |
| WorkingCapital | 196.52M | 202.88M | 157.29M | 182.07M |
| NetTangibleAssets | 95.39M | 206.58M | 161.03M | 185.09M |
| CapitalLeaseObligations | 6.31M | 7.32M | 8.23M | 8.19M |
| CommonStockEquity | 95.39M | 206.58M | 161.03M | 185.09M |
| TotalCapitalization | 95.39M | 206.58M | 161.03M | 185.09M |
| TotalEquityGrossMinorityInterest | 95.39M | 206.58M | 161.03M | 185.09M |
| StockholdersEquity | 95.39M | 206.58M | 161.03M | 185.09M |
| GainsLossesNotAffectingRetainedEarnings | -5.21M | -3.49M | -3.06M | -3.86M |
| OtherEquityAdjustments | -5.21M | -3.49M | -3.06M | |
| RetainedEarnings | -653.17M | -469.73M | -343.08M | -250.18M |
| AdditionalPaidInCapital | 753.73M | 679.75M | 507.13M | 439.10M |
| CapitalStock | 50.00K | 42.00K | 34.00K | 25.00K |
| CommonStock | 50.00K | 42.00K | 34.00K | 25.00K |
| TotalLiabilitiesNetMinorityInterest | 155.38M | 28.82M | 22.18M | 18.79M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 110.21M | 6.01M | 7.14M | 7.21M |
| NonCurrentDeferredLiabilities | 105.88M | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 4.33M | 6.01M | 7.14M | 7.21M |
| LongTermCapitalLeaseObligation | 4.33M | 6.01M | 7.14M | 7.21M |
| CurrentLiabilities | 45.17M | 22.81M | 15.03M | 11.58M |
| CurrentDeferredLiabilities | 11.00M | 0.00 | ||
| CurrentDeferredRevenue | 11.00M | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 1.98M | 1.30M | 1.09M | 977.00K |
| CurrentCapitalLeaseObligation | 1.98M | 1.30M | 1.09M | 977.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 16.12M | 6.69M | 4.21M | 4.17M |
| PayablesAndAccruedExpenses | 16.07M | 14.82M | 9.74M | 6.43M |
| CurrentAccruedExpenses | 11.18M | 5.71M | 4.92M | 2.79M |
| Payables | 4.88M | 9.11M | 4.82M | 3.64M |
| AccountsPayable | 4.88M | 9.11M | 4.82M | 3.64M |
| TotalAssets | 250.77M | 235.40M | 183.20M | 203.88M |
| TotalNonCurrentAssets | 9.08M | 9.71M | 10.88M | 10.23M |
| OtherNonCurrentAssets | 1.55M | 567.00K | 106.00K | 193.00K |
| NetPPE | 7.53M | 9.15M | 10.77M | 10.04M |
| AccumulatedDepreciation | -4.75M | -3.71M | -2.96M | -2.42M |
| GrossPPE | 12.28M | 12.86M | 13.73M | 12.46M |
| Leases | 3.09M | 2.86M | 2.85M | 2.00M |
| OtherProperties | 8.20M | 9.33M | 10.23M | 10.02M |
| MachineryFurnitureEquipment | 984.00K | 671.00K | 647.00K | 447.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 241.69M | 225.69M | 172.33M | 193.65M |
| OtherCurrentAssets | 4.92M | |||
| PrepaidAssets | 5.93M | 4.42M | 4.31M | 10.64M |
| Receivables | 15.14M | 10.87M | 18.64M | 16.81M |
| OtherReceivables | 11.00M | |||
| TaxesReceivable | 2.31M | 9.46M | 17.99M | 15.92M |
| AccruedInterestReceivable | 1.83M | 1.41M | 654.00K | 888.00K |
| CashCashEquivalentsAndShortTermInvestments | 220.62M | 210.40M | 149.38M | 166.20M |
| OtherShortTermInvestments | 89.00M | 178.61M | 93.14M | 135.47M |
| CashAndCashEquivalents | 131.62M | 31.79M | 56.24M | 30.73M |
| Line Item | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|
| FreeCashFlow | -153.84M | -89.67M | -76.46M | -79.06M |
| RepaymentOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 55.91M | 96.94M | 56.58M | 0.00 |
| CapitalExpenditure | -929.00K | -443.00K | -1.20M | -931.00K |
| EndCashPosition | 132.27M | 31.79M | 56.24M | 30.73M |
| BeginningCashPosition | 31.79M | 56.24M | 30.73M | 50.59M |
| EffectOfExchangeRateChanges | 2.64M | -1.21M | 1.24M | -1.17M |
| ChangesInCash | 97.84M | -23.24M | 24.27M | -18.69M |
| FinancingCashFlow | 159.73M | 150.71M | 58.12M | 1.58M |
| CashFlowFromContinuingFinancingActivities | 159.73M | 150.71M | 58.12M | 1.58M |
| NetOtherFinancingCharges | 98.04M | |||
| ProceedsFromStockOptionExercised | 5.78M | 53.77M | 1.53M | 1.58M |
| NetCommonStockIssuance | 55.91M | 96.94M | 56.58M | 0.00 |
| CommonStockIssuance | 55.91M | 96.94M | 56.58M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | ||
| NetLongTermDebtIssuance | 0.00 | 0.00 | ||
| LongTermDebtPayments | 0.00 | 0.00 | ||
| InvestingCashFlow | 91.02M | -84.72M | 41.41M | 57.86M |
| CashFlowFromContinuingInvestingActivities | 91.02M | -84.72M | 41.41M | 57.86M |
| NetInvestmentPurchaseAndSale | 91.95M | -84.28M | 42.61M | 58.79M |
| SaleOfInvestment | 122.52M | 104.95M | 140.86M | 195.71M |
| PurchaseOfInvestment | -30.57M | -189.23M | -98.25M | -136.92M |
| NetPPEPurchaseAndSale | -434.00K | -42.00K | -1.20M | -931.00K |
| PurchaseOfPPE | -434.00K | -42.00K | -1.20M | -931.00K |
| CapitalExpenditureReported | -495.00K | -401.00K | 0.00 | 0.00 |
| OperatingCashFlow | -152.91M | -89.23M | -75.26M | -78.13M |
| CashFlowFromContinuingOperatingActivities | -152.91M | -89.23M | -75.26M | -78.13M |
| ChangeInWorkingCapital | 15.04M | 15.17M | 7.41M | -12.32M |
| ChangeInOtherWorkingCapital | 10.56M | |||
| ChangeInOtherCurrentAssets | -22.00K | |||
| ChangeInPayablesAndAccruedExpense | 9.46M | 7.53M | 3.04M | 2.16M |
| ChangeInAccruedExpense | 14.43M | 3.21M | 1.93M | 472.00K |
| ChangeInPayable | -4.97M | 4.32M | 1.11M | 1.69M |
| ChangeInAccountPayable | -4.97M | 4.32M | 1.11M | 1.69M |
| ChangeInPrepaidAssets | -1.36M | -538.00K | 6.69M | -9.28M |
| ChangeInReceivables | -3.62M | 8.18M | -2.32M | -5.20M |
| OtherNonCashItems | 6.24M | -12.00K | 84.00K | 179.00K |
| StockBasedCompensation | 12.29M | 21.91M | 9.92M | 11.09M |
| AmortizationOfSecurities | 14.00K | 92.00K | 988.00K | 2.56M |
| DepreciationAmortizationDepletion | 941.00K | 816.00K | 718.00K | 564.00K |
| DepreciationAndAmortization | 941.00K | 816.00K | 718.00K | 564.00K |
| OperatingGainsLosses | -3.99M | -565.00K | -1.48M | 2.13M |
| GainLossOnInvestmentSecurities | 189.00K | -1.32M | 139.00K | 581.00K |
| NetForeignCurrencyExchangeGainLoss | -4.17M | 760.00K | -1.62M | 1.55M |
| NetIncomeFromContinuingOperations | -183.44M | -126.64M | -92.91M | -82.34M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for KALV
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|